Brief: Zyversa Therapeutics Inc Says Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
08/09/2023 21:23
Sept 8 (Reuters) - Zyversa Therapeutics Inc ZVSA.O :
* ZYVERSA THERAPEUTICS INC - RECEIVED NOTICE OF DELISTING OR
FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD;
TRANSFER OF LISTING FROM NASDAQ
Further company coverage: ZVSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zyversa Therapeutics
See all newsBrief: ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million
Brief: ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity
Brief: Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation
Brief: ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status
Brief: Zyversa Therapeutics Files For Prospectus Related To Offer & Resale Of Up To 1.6 Million Shares Of Common Stock By Selling Stockholder - SEC Filing